磷酸酶张力蛋白同源物表达与西妥昔单抗在结直肠癌患者中的疗效相关：一项荟萃分析。
Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis.
机构信息
Department of Oncology, Nanjing First Hospital, Southeast University, Nanjing 210006, Jiangsu Province, China.
出版信息
World J Gastroenterol. 2012 Jun 7;18(21):2712-8. doi: 10.3748/wjg.v18.i21.2712.
AIM
To investigate the correlation between expression of phosphatase and tensin homolog (PTEN) and cetuximab effects in colorectal cancer.
METHODS
We searched PubMed, EMBASE and ASCO to identify eligible studies. Finally, 8 randomized control studies were included in the meta-analysis. STATA 10.0 Software was used to investigate heterogeneity among individual studies and to summarize all the studies. Risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the strength of the association.
RESULTS
Compared with 20 of 266 patients with loss of PTEN, 206 of 496 patients with intact PTEN protein expression had a better objective response rate to cetuximab-based therapy (RR, 4.75; 95% CI, 2.59-8.72; P < 0.001). PTEN positivity was associated with better progression-free survival (PFS) (HR, 0.675; 95% CI, 0.473-0.964; P = 0.031) but not with better overall survival (OS) (HR, 0.608; 95% CI, 0.411-0.899; P = 0.013). In patients with KRAS wild-type status, PTEN positivity did not predict a longer PFS or OS (PFS: HR, 0.707; 95% CI, 0.440-1.138; P = 0.154; OS: HR, 0.943; 95% CI, 0.646-1.377; P = 0.761).
CONCLUSION
Expression of PTEN is related to the effect of cetuximab in colorectal cancer patients and should be considered in treatment with cetuximab.
目的
研究磷酸酶与张力蛋白同源物（PTEN）的表达与结直肠癌患者接受西妥昔单抗治疗效果之间的相关性。
方法
我们检索了 PubMed、EMBASE 和 ASCO 以确定符合条件的研究。最终，有 8 项随机对照研究被纳入荟萃分析。使用 STATA 10.0 软件来研究个体研究之间的异质性，并对所有研究进行总结。风险比（RR）和风险比（HR）及其 95%置信区间（CI）用于评估关联的强度。
结果
与 266 例 PTEN 缺失患者中的 20 例相比，496 例 PTEN 蛋白表达完整的患者中，有 206 例对基于西妥昔单抗的治疗有更好的客观缓解率（RR，4.75；95%CI，2.59-8.72；P<0.001）。PTEN 阳性与更好的无进展生存期（PFS）相关（HR，0.675；95%CI，0.473-0.964；P=0.031），但与更好的总生存期（OS）无关（HR，0.608；95%CI，0.411-0.899；P=0.013）。在 KRAS 野生型患者中，PTEN 阳性并不能预测更长的 PFS 或 OS（PFS：HR，0.707；95%CI，0.440-1.138；P=0.154；OS：HR，0.943；95%CI，0.646-1.377；P=0.761）。
结论
PTEN 的表达与结直肠癌患者接受西妥昔单抗治疗的效果有关，在使用西妥昔单抗治疗时应考虑这一点。
Zotero 插件